Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression Meeting Abstract
| Authors: | Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; Apollo, A.; Owens, C.; Funt, S. A.; Shah, N. J.; Iyer, G.; Aggen, D. H.; Ostrovnaya, I.; Rosenberg, J. E. |
| Abstract Title: | Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S1157 |
| End Page: | S1158 |
| Language: | English |
| ACCESSION: | WOS:001326612902617 |
| DOI: | 10.1016/j.annonc.2024.08.2089 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2003P -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
